www.StockMarketingInc.com: Don't Miss Out On The Hottest Newsletter!! Hear It Here First!! WZE- "Wizzard Media Launches 24 New iPhone Apps "

Nov 5, 2009 STOCK MARKETING INC PRESENTS :

(NYSE: WZE - Wizzard Software Corp.) (NASDAQ: VARI - Varian, Inc.) (NASDAQ: GNVC - GenVec, Inc.) (NASDAQ: IMAX - Imax Corp.) (NASDAQ: TASR - TASER International, Inc.) (NASDAQ: IFLO - I-Flow Corp.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NYSE: WZE - Wizzard Software Corp.)

LATEST NEWS!!

Wizzard Media Launches 24 New iPhone Apps

PITTSBURGH, Nov 05, 2009 -- Wizzard Media (NYSE Amex: WZE), the world's largest podcasting network, today announced the launch of 24 new iPhone(R) Apps available for sale in the App store including Investors Business Daily Editorials and Alaska HDTV. The average price for the new Apps is $1.99.

The newly launched Apps are iPhone companion Apps for popular podcasts on the Wizzard Media Network, offering audiences one-click access to the podcast directly on their iPhone or iPod Touch(R), bonus content and new social communication features creating an unprecedented level of audience engagement.

Wizzard recently announced 2009 third quarter network numbers of 12,281 podcasts downloaded 332 million times in the quarter by over 18 million unique monthly audience members. Approximately 70% of the audience for podcasts subscribe through iTunes(R) from which users download podcasts for their iPhone and iPod(R). Until recently, Wizzard's only means to derive revenues was through podcast publishing services as well as advertising sales.

With the launch of the iPhone App store in iTunes, Wizzard created a unique iPhone App that can be quickly customized for each podcast and allows podcast publishers to generate a new revenue stream by marketing their own iPhone App directly to their audience. Wizzard shares in this revenue with the podcast publisher. Now, with Wizzard's unique podcast companion App for the iPhone, participating podcasts can market their customized App to their audience and then drive future reoccurring episode and subscription sales through a process called in-App purchasing.

Analysts project the App market to be a $1.0 billion market today, headed for $4.0 billion by 2012. With the holiday season approaching and the recent launch of the iPhone in China, Wizzard's Management believes the number of people using iPhones and iPod Touches to consume podcasts and interact with Apps will continue to grow well beyond the current 50 million user base.

Having launched the first podcast App only 95 days ago, Wizzard Media already has launched 70 iPhone Apps with 60 more Apps awaiting approval. Additionally, Wizzard has exclusively licensed 12 high quality, game type Apps and is currently marketing them through targeted podcasts across the Wizzard Media Network. Select podcast Apps on the Wizzard Network have already helped to convert approximately 15% of their audience from free, to paid, in the first 75 days since launch.

"We think our podcast companion App initiative is a game changer for the podcasting industry. We believe the next great opportunity on the web for media is the seamless combination of three trends -- publishing services, advertising and micropayments for App sales," says Dave Mansueto, co-founder Wizzard Media. "Now, podcasting becomes a platform that converts audiences to revenue, accelerated by the micropayment billing process that Apple has created with the App store. We believe this new process is the model for how digital media is published, audiences are grown and revenues derived." "We know there is strong demand for the podcasts we distribute seeing downloads grow from 400 million to well over 1 billion in the last three years and monthly audiences grow from 4 million to 18 million," says Laurie Sims, President of Wizzard Media. "Now that we have a method to charge for podcast content and subscriptions, we believe there is dramatic change ahead for the podcast industry. Unlike most Apps in the App store, podcasters have a distinct advantage to successfully market their App in iTunes due to the fact that they have already built a substantial audience for their product through iTunes." About Wizzard Media: Wizzard Media provides publishing and distribution services to podcasters and monetization services for podcasters. Wizzard Media is the industry's leading podcasting network with an unprecedented 1.2 billion download requests in 2008. Podcasts are a means for independent and professional content creators to publish audio and video shows for the world to enjoy over the Internet or on mp3 players, such as the Apple iPod(R), iPhone(R) and the Microsoft Zune(R). Podcasting is a relatively new phenomenon, but Wizzard Media collectively broadcasts millions of podcast downloads per day through media aggregators like Apple's iTunes and Microsoft's Zune Marketplace. For more information, please visit www.wizzardsoftware.com/media . Wizzard Media is a division of Wizzard Software, a leader in speech technology distribution and development.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: VARI - Varian, Inc.)

LATEST NEWS!!

New Triple-Quadrupole Mass Spectrometer from Varian, Inc. Enhances Sensitivity in LC/MS

--- Novel API Interface and Ion Optics Improve Performance

PALO ALTO, Calif., Nov 05, 2009 -- Varian, Inc. (NasdaqGS: VARI) announced today the release of the 325-MS triple-quadrupole LC/MS (liquid chromatograph/mass spectrometer) for the efficient detection and identification of chemical compounds in high-throughput laboratories performing environmental, food safety, and toxicology analyses.

Analytical chemists face the challenge of identifying a growing list of compounds from an increasing number of samples in a variety of matrices. To remain competitive, laboratories must maximize the number of compounds they can detect and quantify in a single analytical run while minimizing the time spent on maintaining the instrument. The 325-MS, Varian's next generation LC/MS triple-quadrupole mass spectrometer features a novel ESI ion source and improved ion-optics that jointly enhance sensitivity, ruggedness and throughput.

At the heart of the 325-MS is Varian's patent pending vESI(TM) ion source, a vortex ESI ion source that improves sensitivity by increasing the efficiency of the desolvation process. A vortex of drying-gas facilitates ion desolvation at lower temperatures, accommodating a wider range of flow-rates for small molecule analysis as well as biomolecules without compromising system performance. Chemists can take advantage of the improved sensitivity by either lower detection limits for some compounds or by analyzing more compounds in a single run, increasing throughput and reducing the cost per analysis.

Gold-Guard(TM) ion optics (patent pending) provide enhanced contamination resistance. The 325-MS requires little to no cleaning in order to maintain a high-level of reproducibility and accuracy even after repeated injections of analytes suspended in a complex matrix. Fewer cleanings mean greater uptime and more productivity, again reducing the cost per analysis.

In order to help customers get the most from their instrument, Varian also provides consumables, including sample preparation tools and HPLC columns, as well as applications assistance and a comprehensive selection of support and training options.

"Maintaining and even increasing throughput is essential for laboratories performing environmental analyses and food safety testing," said Martin O'Donoghue, Senior Vice President, Scientific Instruments, Varian, Inc. "The 325-MS allows users to gather more information from each run while spending less time maintaining the instrument." For more technical information about Varian products, please visit http://www.varianinc.com/products/ About Varian, Inc.

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science, environmental, energy, and applied research and other applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc.'s common stock is traded on the NASDAQ Global Select Market under the symbol "VARI." Further information is available on the company's Web site at http://www.varianinc.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: GNVC - GenVec, Inc.)

LATEST NEWS!!

GenVec Signs New Contract to Support HIV and Influenza Vaccine Development

GAITHERSBURG, Md., Nov 05, 2009 -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will receive approximately $2.6 million.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) Under the contract, the vaccines would be comprised of genetic material supplied by the VRC and adenoviral vectors supplied by GenVec.

"This new contract supports important efforts in HIV and influenza. Given the heightened concerns about influenza, this contract is timely and we look forward to applying our novel technology to this problem," stated Dr. Paul Fischer, GenVec's President and CEO. "In particular, we are looking forward to working on a universal flu vaccine, which has the potential to protect against seasonal and pandemic outbreaks." Work under this contract will include generation of HIV vaccine candidates, generation of a universal flu vaccine candidate, process and assay development for manufacture of vaccine candidates for clinical testing, and continued support of the HIV vaccine candidates currently in clinical testing.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product TNFerade is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, influenza, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: IMAX - Imax Corp.)

LATEST NEWS!!

IMAX Corporation Receives Commitment Letter From Wachovia With Participation of Export Development Canada for New $75 Million Credit Facility

TORONTO, Nov. 5, 2009 -- IMAX Corporation (Nasdaq:IMAX) (TSX:IMX) today announced that it has entered into a commitment letter with Wachovia Capital Finance Corporation pursuant to which Wachovia, with the participation of Export Development Canada, has committed to provide a four-year senior secured $75 million credit facility. Upon execution of definitive documents, the credit facility will consist of revolving loans of up to $40 million and a term loan of $35 million. Once completed, the Company intends to use the new facility to finance its future growth and working capital requirements. The proposed credit facility matures on October 31, 2013 and will replace the Company's previous $40 million credit facility which was to mature in October of 2010.

As currently contemplated, borrowings under the credit facility will bear interest at variable rates based on LIBOR or Wachovia's prime rate plus variable margins at the Borrower's option, under which applicable interest rates currently range from 3.03% to 4.03% per annum.

As previously announced on October 2, 2009, the Company called $75 million of its Senior Notes for redemption on December 1, 2009. The Company intends to redeem the remaining $29.4 million of its Senior Notes by year-end.

"This proposed new facility, combined with the redemption of our remaining senior notes, are very important steps toward creating a capital structure that will enable the Company to further realize the growth potential for the IMAX brand," said Richard L. Gelfond, Chief Executive Officer of IMAX Corporation. "We believe our progress throughout this year to strengthen our balance sheet and enhance our financial flexibility is reflective of the early success we have achieved with our new business model and our entry in the digital arena." About IMAX Corporation IMAX Corporation is one of the world's leading entertainment technology companies, specializing in immersive motion picture technologies. The worldwide IMAX network is among the most important and successful theatrical distribution platforms for major event Hollywood films around the globe, with IMAX(R) theatres delivering the world's best cinematic presentations using proprietary IMAX, IMAX(R) 3D, and IMAX DMR(R) technology. IMAX DMR is the Company's groundbreaking digital re-mastering technology that allows it to digitally transform virtually any conventional motion picture into the unparalleled image and sound quality of The IMAX Experience(R). The IMAX brand is recognized throughout the world for extraordinary and immersive entertainment experiences for consumers. As of September 30, 2009, there were 403 IMAX theatres (280 commercial, 123 institutional) operating in 44 countries.

IMAX(R), IMAX(R) 3D, IMAX(R) DMR, Experience It In IMAX(R), The IMAX 3D Experience(R) and The IMAX Experience(R) are trademarks of IMAX Corporation. More information about the Company can be found at www.imax.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: TASR - TASER International, Inc.)

LATEST NEWS!!

TASER International Receives Order for 1,021 TASER X26 ECDs From DeKalb County Police Department SCOTTSDALE, Ariz., Nov 5, 2009) -- TASER International, Inc. (Nasdaq:TASR), a market leader in digital evidence solutions and electronic control devices (ECDs), today announced an order from the DeKalb Country Police Department for 1,021 TASER(R) X26(TM) ECDs and related accessories. The contract was placed with DGG Taser & Tactical Supply.

"The DeKalb County Police Department is pleased with the recent acquisition of 1,021 electronic control devices for our officers. TASERS ECDs are very effective, non-lethal devices that assist officers in their daily functions when confronting violent situations or armed suspects. This is an essential tool in our efforts to reduce injuries to both suspects and officers," said Chief William O'Brien from the DeKalb County Police Department.

"We are thrilled to partner with the DeKalb County Police Department by providing them with products that help minimize risks and increase safety margins for their personnel and those they encounter in the line of duty," said Tom Smith, Chairman and founder of TASER International.

The order is expected to ship in the fourth quarter of 2009.

About TASER International, Inc.

TASER International's products Protect Life and Protect Truth. TASER provides advanced Electronic Control Devices (ECDs) and innovative secured digital evidence collection and management solutions for use in the law enforcement, medical, military, corrections, professional security, and personal safety markets. TASER ECDs use proprietary technology to incapacitate dangerous, combative, or high-risk subjects who pose a risk to law enforcement officers, innocent citizens, or themselves in a manner that is generally recognized as a safer alternative to other uses of force. The TASER(R) AXON(TM), a revolutionary on-officer tactical computer and video/audio recorder, combines with an integrated digital multi-media evidence storage and management platform -- EVIDENCE.COM -- to provide an end-to-end solution to capture, store securely, and analyze digital evidence and information in ways that enables tactical and strategic decision making by law enforcement, as well as for legal evidentiary use. For more information please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: IFLO - I-Flow Corp.)

LATEST NEWS!!

I-Flow Reports Profitable 2009 Third Quarter as Total Revenue Increased 14% to $36.7 Million

Total Revenue for the First Nine Months of 2009 Increased 9%

LAKE FOREST, Calif., Nov 05, 2009 -- I-FLOW CORPORATION (NASDAQ:IFLO) announced today that total revenue for the third quarter ended September 30, 2009 increased 14% to $36.7 million compared to total revenue of $32.2 million for the third quarter of 2008.

Regional Anesthesia (RA) sales of the Company's flagship ON-Q(R) product lines increased 11% for this year's third quarter to $27.5 million compared to $24.8 million for the third quarter of 2008. AcryMed revenues were $0.8 million for this year's third quarter compared to $1.5 million for the third quarter of 2008. The prior year quarter included $0.7 million of sales for temporary pilot production prior to the planned transfer of manufacturing responsibility to a customer. IV Infusion Therapy revenue for the third quarter of 2009 increased 41% to $8.4 million compared to $5.9 million for the third quarter of 2008.

Net income for the third quarter of 2009 increased to $0.7 million, or $0.03 per basic and diluted share. This compares to a net loss of $14.1 million, or $0.57 per basic and diluted share, for the third quarter of 2008. Transaction costs of approximately $0.8 million were incurred during the third quarter of 2009 in connection with the sale process resulting in the recently announced definitive merger agreement with Kimberly-Clark Corporation (Kimberly-Clark) providing for the acquisition of I-Flow by Kimberly-Clark for $12.65 per share in cash. The net loss for the third quarter of 2008 included a purchase accounting write-off of $11.6 million of in-process research and development charges acquired in connection with the acquisition in February 2008 of AcryMed and a $4.6 million non-cash impairment loss on the common shares of InfuSystem Holdings, Inc., formerly HAPC, Inc., owned by I-Flow.

Total revenue for the first nine months of 2009 increased 9% to $104.8 million compared to $96.0 million for the first nine months of 2008. RA sales increased 7% for this year's first nine months to $78.5 million compared to $73.5 million for first nine months of 2008. AcryMed revenues were $2.5 million for this year's first nine months compared to $3.8 million for the same period of 2008. AcryMed's revenue in the prior year period included $1.9 million of sales for temporary pilot production prior to the planned transfer of manufacturing responsibility to a customer. IV Infusion Therapy revenue for the first nine months of 2009 increased 28% to $23.8 million compared to $18.6 million for the first nine months of 2008.

The net loss for the nine months ended September 30, 2009 was $1.8 million, or $0.07 per basic and diluted share. This compares to a net loss for the nine months ended September 30, 2008 of $26.1 million, or $1.05 per basic and diluted share. Transaction costs of approximately $1.0 million were incurred during the nine months ended September 30, 2009 in connection with the sale process resulting in the recently announced definitive merger agreement with Kimberly-Clark. The net loss for the first nine months of 2008 included the purchase accounting write-off of $11.6 million for in-process research and development costs, the $4.6 million for impairment loss and $12.3 million of certain litigation and insurance charges, which consisted of a $3.5 million expense to purchase retroactive insurance policies to significantly increase the Company's product liability insurance coverage and $8.8 million in loss contingency that the Company accrued in connection with ongoing litigation.

At September 30, 2009, I-Flow reported net working capital of approximately $79.3 million, including cash, cash equivalents and short-term investments of $54.3 million, and stockholders' equity of $118.3 million.

About I-Flow

I-Flow Corporation (www.IFLO.com) is improving clinical and economic outcomes by designing, developing and marketing technically advanced, low cost delivery systems and innovative surgical products for post-surgical pain relief and surgical site care.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

For additional information, please contact info@StockMarketingInc.com or call 1-866-583-8960

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: accounting, acquisition, advertising, alaska, amex, arizona, billing, business, california, canada, cancer, ceo, china, clinical, commercial, computer, contamination, contract, disease, drugs, email, e-mail, entertainment, equity, export, finance, food, gold, health, hiv, insurance, interest rates, investment opinion, law enforcement, legal, manufacturer, manufacturing, market, marketing, media, medical, merger, military, mp3, nasdaq, nyse, optics, patent, pilot, police, president, prime rate, productivity, products, publisher, publishing, rates, research, research and development, respiratory, revenue, sales, science, security, ship, software, subscription, technology, toronto, training, vaccine, video, web